Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer

References

• Survival of Cancer Patients in Europe: The EUROCARE-2 study. IARC Sci Publ. 1999;151:1–572.
   Google Scholar
• Gibson MK, Forastiere AA. Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art. Curr Opin Oncol. 2004;16:220–4.
   PubMed Web of Science ®Google Scholar
• Clark WH. Tumour progression and the nature of cancer. Br J Cancer. 1991;64:631–44.
   PubMed Web of Science ®Google Scholar
• Hald J, Rasmussen N, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1995;41:243–50.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, . In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol. 1994;12:1475–83.
   PubMed Web of Science ®Google Scholar
• Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005;28:258–67.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9:4296–303.
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007;67:8865–73.
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14:3706–15.
   PubMed Web of Science ®Google Scholar
• Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, . Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25:1562–9.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.
   PubMed Web of Science ®Google Scholar
• Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, . Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280–90.
   PubMed Web of Science ®Google Scholar
• Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004;165:1853–63.
   PubMed Web of Science ®Google Scholar
• Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99–146.
   PubMed Web of Science ®Google Scholar
• Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, . Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.
   PubMed Web of Science ®Google Scholar
• Hald J, Rasmussen N, Claesson MH. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol Immunother. 1994;39:383–90.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother. 1988;26:1–10.
   PubMed Web of Science ®Google Scholar
• Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, . Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005; 105:1898–904.
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, . Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379–86.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–57.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26:5233–9.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, . Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–66.
   PubMed Web of Science ®Google Scholar
• Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175: 7046–52.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, . Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173: 7125–30.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332–42.
   PubMed Web of Science ®Google Scholar
• thor Straten P, Guldberg P, Gronbaek K, Hansen MR, Kirkin AF, Seremet T, . In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol. 1999;163:443–7.
   PubMed Web of Science ®Google Scholar
• Guldberg P, Guttler F. ‘Broad-range’ DGGE for single-step mutation scanning of entire genes: application to human phenylalanine hydroxylase gene. Nucleic Acids Res. 1994;22: 880–1.
   Google Scholar
• thor Straten P, Kirkin AF, Siim E, Dahlstrom K, Drzewiecki KT, Seremet T, . Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol. 2000;96:94–9.
   Google Scholar
• Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, . Immunogenicity of Bcl-2 in patients with cancer. Blood. 2005;105:728–34.
   PubMedGoogle Scholar
• Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, . Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169:1984–92.
   PubMed Web of Science ®Google Scholar
• Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005;11:2552–60.
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294–305.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 2005;105:241–50.
   PubMed Web of Science ®Google Scholar
• Desfrancois J, Moreau-Aubry A, Vignard V, Godet Y, Khammari A, Dreno B, . Double positive CD4 CD8 alpha beta T cells: a new tumor-reactive population in human melanomas. PLoS One. 2010;5:e8437.
   Google Scholar
• Huang J, Kerstann KW, Ahmadzadeh M, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol. 2006;176:7726–35.
   PubMed Web of Science ®Google Scholar
• Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, . Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 2008;31:742–51.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007;7:633–42.
   PubMed Web of Science ®Google Scholar
• Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, . Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med. 2001;194:1313–23.
   PubMed Web of Science ®Google Scholar
• Sorensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, . CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res. 2009;15:1543–9.
   PubMed Web of Science ®Google Scholar
• Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr Opin Immunol. 2009;21:190–9.
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, . Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother. 2009;32:415–23.
   PubMed Web of Science ®Google Scholar
• Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455–500.
   PubMedGoogle Scholar